ISO Stock Overview
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
IsoPlexis Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.76 |
| 52 Week High | US$4.55 |
| 52 Week Low | US$0.60 |
| Beta | 0 |
| 1 Month Change | -29.48% |
| 3 Month Change | -45.60% |
| 1 Year Change | -80.57% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.39% |
Recent News & Updates
Shareholder Returns
| ISO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0.07% | -2.1% | -2.4% |
| 1Y | -80.6% | -5.5% | 23.4% |
Return vs Industry: ISO underperformed the US Life Sciences industry which returned -13.4% over the past year.
Return vs Market: ISO underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| ISO volatility | |
|---|---|
| ISO Average Weekly Movement | 13.1% |
| Life Sciences Industry Average Movement | 9.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ISO's share price has been volatile over the past 3 months.
Volatility Over Time: ISO's weekly volatility has decreased from 21% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 290 | Sean Mackay | isoplexis.com |
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services.
IsoPlexis Corporation Fundamentals Summary
| ISO fundamental statistics | |
|---|---|
| Market cap | US$30.28m |
| Earnings (TTM) | -US$106.00m |
| Revenue (TTM) | US$16.76m |
1.8x
P/S Ratio-0.3x
P/E RatioIs ISO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ISO income statement (TTM) | |
|---|---|
| Revenue | US$16.76m |
| Cost of Revenue | US$17.69m |
| Gross Profit | -US$925.00k |
| Other Expenses | US$105.07m |
| Earnings | -US$106.00m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.67 |
| Gross Margin | -5.52% |
| Net Profit Margin | -632.40% |
| Debt/Equity Ratio | 112.3% |
How did ISO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/22 06:55 |
| End of Day Share Price | 2023/03/20 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
IsoPlexis Corporation is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Puneet Souda | Leerink Partners LLC |
| Tejas Savant | Morgan Stanley |
| Max Masucci | TD Cowen |